
Subject: da gerad spiro gute karten hat: testo+spiro=17 β estradiol?

Posted by [kkoo](#) on Tue, 30 May 2006 19:26:45 GMT

[View Forum Message](#) <> [Reply to Message](#)

fuselkopf schrieb "... zumal spiro auch testosteron in der kopfhaut in 17 β estradiol umwandeln kann"

kann das mal jemand näher erläutern?

Subject: Re: da gerad spiro gute karten hat: testo+spiro=17 β estradiol?

Posted by [fuselkopf](#) on Tue, 30 May 2006 21:19:58 GMT

[View Forum Message](#) <> [Reply to Message](#)

schau halt mal nach, ob du ne untersuchung zu findest... ich meine dass die auf minoxidil.com literatur angeben...

Subject: Re: da gerad spiro gute karten hat: testo+spiro=17 β estradiol?

Posted by [fuselkopf](#) on Tue, 30 May 2006 21:23:28 GMT

[View Forum Message](#) <> [Reply to Message](#)

Zitat:1. Hamilton JB: Male hormone stimulation is prerequisite and an incitant in common baldness. Am J Anat 71:451-480, 1942

2. Rattner H: Ordinary baldness. Arch Dermatol Syph 44:201-213, 1941

3. Rook A, Dawber R: Diseases of the Hair and Scalp. Oxford, Blackwell Scientific Publications, 1982

4. Baden HP: Diseases of the Hair and Nails. Chicago, Year Book Medical Publishers, 1987

5. Lattanand A, Johnson WC: Male pattern alopecia: A histopathologic and histochemical study. J Cutan Pathol 2:58-70, 1975

6. Blauer M, Vaalasti A, Pauli SL, Ylikomi T, Joensuu T, Tuohimaa P: Location of androgen receptor in human skin. J Invest Dermatol 97:264-268, 1991

7. Menard RH, Stripp B, Gillette JR: Spironolactone and testicular cytochrome P-450: Decreased testosterone formation in several species and changes in hepatic drug metabolism. Endocrinology 1974;94:1628-1636

8. Menard RH, Martin HF, Stripp B, et al: Spironolactone and cytochrome P-450: Impairment of steroid hydroxylation in the adrenal cortex. Life Sci 1975;15:1639-1648

9. Schapiro G and Evron S. A novel use of Spironolactone:treatment of hirsutism. J Clin Endocrinol Metab. 1988;51:429-432

10. Cumming D, Yang J, Rebar R, Yen S.: Treatment of hirsutism with Spironolactone. JAMA. 1982;247:1295-8.
11. Boisselle A, Tremblay RR: Clinical usefulness of spironolactone in the treatment of acne and hirsutism, abstracted. Clin Res 1978;26:840A
12. Yamamoto A, Ito M. Topical spironolactone reduces sebum secretion rates in young adults. J Dermatol, 1996 Apr,23:4,243-6
13. Berardesca E, Gabba P, Ucci G, Borroni G, Rabbiosi G: Topical spironolactone inhibits dihydrotestosterone receptors in human sebaceous glands: an autoradiographic study in subjects with acne vulgaris. Int J Tissue React 10:115-119, 1988
14. Burke BM, Cunliffe WJ: Oral spironolactone therapy for female patients with acne, hirsutism or androgenetic alopecia. Br J Dermatol 112:124-125, 1985
15. Stripp B, Taylor AA, Bartter FC, et al: Effect of spironolactone on sex hormones in man. J Clin Endocrinol Metabol 1975;41:777-781
16. Mann NM: Gynecomastia during therapy with spironolactone. JAMA 190:160-162,1963
17. Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH: Pathophysiology of spironolactone-induced gynecomastia. Ann Int Med 87:398-403, 1977
18. Corval P, Michaud A, Menard J, et al: Antiandrogenic effect of spironolactones: Mechanism of action.
Endocrinology 1975;97:52-8
19. Messina M, Manieri C, Musso MC, Pastorino R.: Oral and topical spironolactone therapies in skin androgenization. anminerva Med, 1990 Apr-Jun,32:2,49-55
20. Wendt A, Hasan SH, Heinz I, Tauber U: Systemic effects of local antiandrogen therapy. Arch Dermatol Res 273:171,1982
21. Price VH: Testosterone metabolism in the skin: A review of its function in androgenetic alopecia, acne vulgaris, and idiopathic hirsutism including recent studies with antiandrogens. Arch Dermatol 1975;111:1496-1502
22. Stoughton RB: Penetration of drugs through the skin. Dermatologica 152 (suppl): 27-36, 1976
23. Matias JR, Malloy V, Orentreich N: Synergistic antiandrogenic effects of topical combinations of 5 alpha reductase and androgen receptor inhibitors in the hamster sebaceous glands. J Invest Dermatol 91:429-433, 1988
24. Takayasu S, Wakimoto H, Itami S, Sano S: Activity of testosterone 5 alpha-reductase in various tissues of human skin. J Invest Dermatol 74:187-191,1980

25. Sawaya ME, Hoenig LS, Hsia SL: Increased androgen binding capacity in sebaceous glands in scalp of male pattern baldness. J Invest Dermatol 92:91-95, 1988, Martin HF, Stripp B, et al: SpiroH

Naja, die Studien stammen teilweise aus den 40igern
Keine Ahnung was man davon zu halten hat...

Subject: uff - -
Posted by [kkoo](#) on Tue, 30 May 2006 21:54:22 GMT
[View Forum Message](#) <> [Reply to Message](#)

mmh, leider gibts da meist nur abstracts...

anbei eine grafik (aus: http://www.klinikum-dessau.de/klinik/klinikde/kl_ha/literatur/antiand.pdf)

- ich dachte man würde es da sehen könnten, ist aber nicht bzw. ich bin ja auch nur laie, und sehe die beziehung nicht...

File Attachments

1) [Untitled-1 copy.jpg](#), downloaded 295 times

